Thiogenesis Therapeutics, Corp. (TTIPF)
OQB · Healthcare · Biotechnology
$0.37
+0.00%
Closing price as of 2026-10-27 · Source: TEK2day Finance
Key Metrics
Market Cap
$26.2M
Shares Outstanding
70.0M
Exchange
OQB
Currency
USD
About Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Quarterly Financials (CAD)
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.4M) | (1.7M) | (918K) | (1.5M) |
| Net Income | (2.4M) | (1.7M) | (912K) | (1.5M) |
| Diluted EPS | (CAD 0.05) | (CAD 0.02) | (CAD 0.03) |
Annual Financials (CAD)
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.0M) | (5.2M) | (3.6M) | (7.4M) |
| Net Income | (3.9M) | (5.1M) | (3.1M) | (7.4M) |
| Diluted EPS | (CAD 0.16) | (CAD 0.13) | (CAD 0.07) | (CAD 0.15) |